Novel Strategies for Inducing Glycemic Remission during the Honeymoon Phase of Type 2 Diabetes

Canadian Journal of Diabetes

Volumn 39, Issue 5, 2015, Pages S142-S147

  Retnakaran, Ravi ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Beta cell function; GLP 1; Short term intensive insulin therapy

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; LIRAGLUTIDE; PLACEBO; SITAGLIPTIN; ANTIDIABETIC AGENT; INSULIN;

APOPTOSIS; CELL FUNCTION; CELL LOSS; DISEASE COURSE; DISEASE DURATION; GLUCOSE BLOOD LEVEL; GLUCOTOXICITY; GLYCEMIC CONTROL; GLYCEMIC REMISSION; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INDUCTION CHEMOTHERAPY; INSULIN RELEASE; INSULIN TREATMENT; INTENSIVE INSULIN THERAPY; MAINTENANCE THERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PREGNANCY DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SHORT COURSE THERAPY; TREATMENT INDICATION; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; EARLY DIAGNOSIS; HYPERGLYCEMIA; METABOLISM; PREDIABETIC STATE; REMISSION; SECRETION (PROCESS); TRENDS;

DIABETES MELLITUS, TYPE 2; EARLY DIAGNOSIS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INDUCTION CHEMOTHERAPY; INSULIN; INSULIN-SECRETING CELLS; PREDIABETIC STATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION;

EID: 84955596309     PISSN: 14992671     EISSN: 23523840     Source Type: Journal    
DOI: 10.1016/j.jcjd.2015.08.007     Document Type: Review

References (39)

1. Turner R.C., Cull C.A., Frighi V., et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999, 281:2005-2012.
2. Kahn S.E., Zraika S., Utzschneider K.M., et al. The beta cell lesion in type 2 diabetes: There has to be a primary functional abnormality. Diabetologia 2009, 52:1003-1012.
3. Retnakaran R. Joe Doupe lecture: Emerging strategies for the preservation of pancreatic beta-cell function in early type 2 diabetes. Clin Invest Med 2014, 37:E414-20.
4. Wajchenberg B.L. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007, 28:187-218.
5. Kato N. Insights into the genetic basis of type 2 diabetes. J Diabetes Investig 2013, 4:233-244.
6. Retnakaran R., Qi Y., Sermer M., et al. Beta-cell function declines within the first year postpartum in women with recent glucose intolerance in pregnancy. Diabetes Care 2010, 33:1798-1804.
7. Xiang A.H., Kawakubo M., Trigo E., et al. Declining beta-cell compensation for insulin resistance in Hispanic women with recent gestational diabetes mellitus: Association with changes in weight, adiponectin, and C-reactive protein. Diabetes Care 2010, 33:396-401.
8. Retnakaran R., Qi Y., Ye C., et al. Hepatic insulin resistance is an early determinant of declining beta-cell function in the first year postpartum following glucose intolerance in pregnancy. Diabetes Care 2011, 34:2431-2434.
9. Kramer C.K., Swaminathan B., Hanley A.J., et al. Each degree of glucose intolerance in pregnancy predicts distinct trajectories of beta-cell function, insulin sensitivity and glycemia in the first 3 years postpartum. Diabetes Care 2014, 37:3262-3269.
10. Retnakaran R., Qi Y., Harris S.B., et al. Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance. Diabetes Care 2011, 34:1601-1604.
11. Holman R.R. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract 1998, 40(Suppl.):S21-5.
12. Butler A.E., Janson J., Bonner-Weir S., et al. Beta-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52:102-110.
13. Rahier J., Guiot Y., Goebbels R.M., et al. Pancreatic β-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 2008, 10(Suppl. 4):32-42.
14. Halban P.A., Polonsky K.S., Bowden D.W., et al. Beta-cell failure in type 2 diabetes: Postulated mechanisms and prospects for prevention and treatment. Diabetes Care 2014, 37:1751-1758.
15. Kramer C.K., Choi H., Zinman B., et al. Determinants of reversibility of beta-cell dysfunction in response to short-term intensive insulin therapy in early type 2 diabetes. Am J Physiol Endocrinol Metab 2013, 305:E1398-407.
16. Retnakaran R., Zinman B. Short-term intensified insulin treatment in type 2 diabetes: Long-term effects on beta-cell function. Diabetes Obes Metab 2012, 14(Suppl. 3):161-166.
17. Poitout V., Robertson R.P. Glucolipotoxicity: Fuel excess and beta-cell dysfunction. Endocr Rev 2008, 29:351-366.
18. Brunzell J.D., Robertson R.P., Lerner R.L., et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 1976, 42:222-229.
19. Retnakaran R., Drucker D.J. Intensive insulin therapy in newly diagnosed type 2 diabetes. Lancet 2008, 371:1725-1726.
20. Kramer C.K., Zinman B., Retnakaran R. Short-term intensive insulin therapy and its impact on type 2 diabetes: A systematic review and meta-analysis. Lancet Diabetes Endocrinol 2013, 1:28-34.
21. Ilkova H., Glaser B., Tunckale A., et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997, 20:1353-1356.
22. Park S., Choi S.B. Induction of long-term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy. Diabetes Metab Res Rev 2003, 19:124-130.
23. Li Y., Xu W., Liao Z., et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004, 27:2597-2602.
24. Ryan E.A., Imes S., Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004, 27:1028-1032.
25. Chen H., Ren A., Hu S., et al. The significance of tumor necrosis factor-alpha in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Res Clin Pract 2007, 75:327-332.
26. Weng J., Li Y., Xu W., et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: A multicenter randomised parallel-group trial. Lancet 2008, 371:1753-1760.
27. Chen H.S., Wu T.E., Jap T.S., et al. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 2008, 31:1927-1932.
28. Chen A., Huang Z., Wan X., et al. Attitudes toward diabetes affect maintenance of drug-free remission in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion treatment. Diabetes Care 2012, 35:474-481.
29. Retnakaran R., Yakubovich N., Qi Y., et al. The response to short-term intensive insulin therapy in type 2 diabetes. Diabetes Obes Metab 2010, 12:65-71.
30. Hu Y., Li L., Xu Y., et al. Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and β-cell function in subjects with long-term remission. Diabetes Care 2011, 34:1848-1853.
31. Stein C., Kramer C., Zinman B., et al. Clinical predictors and time course of the improvement in beta-cell function with short-term intensive insulin therapy in patients with type 2 diabetes. Diabet Med 2015, 32:645-652.
32. Kramer C.K., Zinman B., Choi H., et al. Effect of short-term intensive insulin therapy on post-challenge hyperglucagonemia in early type 2 diabetes. J Clin Endocrinol Metab 2015, 100:2987-2995.
33. Kramer C.K., Choi H., Zinman B., et al. Glycemic variability in patients with early type 2 diabetes: The impact of improvement in beta-cell function. Diabetes Care 2014, 37:1116-1123.
34. Kramer C.K., Vuksan V., Choi H., et al. Emerging parameters of the insulin and glucose response on the oral glucose tolerance test: Reproducibility and implications for glucose homeostasis in individuals with and without diabetes. Diabetes Res Clin Pract 2014, 105:88-95.
35. Retnakaran R., Qi Y., Opsteen C., et al. Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral anti-diabetic medications: A pilot study with sitagliptin. Diabetes Obes Metab 2010, 12:909-915.
36. Opsteen C., Qi Y., Zinman B., et al. Effect of short-term intensive insulin therapy on quality of life in type 2 diabetes. J Eval Clin Pract 2012, 18:256-261.
37. Retnakaran R., Kramer C.K., Choi H., et al. Liraglutide and the preservation of pancreatic beta-cell function in early type 2 diabetes: The LIBRA trial. Diabetes Care 2014, 37:3270-3278.
38. Eng C., Kramer C.K., Zinman B., et al. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: A systematic review and meta-analysis. Lancet 2014, 384:2228-2234.
39. Weng J., Retnakaran R., Ariachery C.A., et al. Short-term intensive insulin therapy at diagnosis in type 2 diabetes: Plan for filling the gaps. Diabetes Metab Res Rev 2015, 31:537-544.